Chronic Obstructive Pulmonary Disease
Conditions
Brief summary
Pulmonary rehabilitation (PR) is one of the cornerstones of care for people with COPD together with smoking cessation and medical treatment. Despite the compelling evidence for its benefits, pulmonary rehabilitation is delivered to less than 30% of patients with COPD. Access to PR are particularly challenging, and especially for those with the most progressed stages of the disease. Pulmonary Tele-rehabilitation (PTR) and Home-based pulmonary rehabilitation (HPR) are two emerging models using health-care supportive technology that have proven equivalent to the conventional PR programs in patients with COPD who are able and willing to participate in conventional PR. However, much remain unknown regarding patients with COPD unable to access and participate in the conventional out-patient hospital- or community-based PR when offered during routine consultation. No studies have been conducted to specifically intervene towards this group. Response from emerging rehabilitation models for this specific group is a black box with no substantial research. To fulfill its potential of relevance, results from emerging models, such as Pulmonary Telerehabilitation and Home-based pulmonary rehabilitation must be of clinical relevance, and superior to the current 'usual care' (medication and scheduled follow-up control) in patients with COPD unable to access and participate in the conventional out-patient hospital- or community-based PR when offered during routine consultation.
Detailed description
This trial will investigate if pulmonary tele-rehabilitation (PTR) and home-based pulmonary rehabilitation (HPR) leads to respiratory symptom relief (CAT score) and improvements on secondary outcomes in patients unable to access conventional rehabilitation programs (standard PR offer). Our hypotheses in a three-arm RCT design are 1. PTR and HPR will be equivalent to each other 2. PTR and HPR will be superior to usual care, that is the control group (CON - no intervention)
Interventions
BEHAVIORALpulmonary tele-rehabilitation (PTR)
PTR is delivered from promoter hospital to a group of 4-6 patients who exercise at home and communicate via tablet-camera. Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks (primary endpoint). Specific exercises are evidence-based; been used in several intervention studies on patients with COPD. Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations. The education sessions consist of dialogue, reflections around empowerment and better living with COPD. Every fourth education session consists of 25 min Mindfulness exercises developed for COPD patients. After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline).
HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle-endurance based exercise; 3-days/weekly for 10-weeks (primary endpoint). Exercises are evidence-based; used in several intervention studies on patients with COPD and involves larger muscle groups with 50/50 exercises for upper/lower extremities. First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of mindfulness exercises and educationbook. The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to COPD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients' preference). After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline).
BEHAVIORALControl
Receive usual care; medication, scheduled follow-up visit and possible phone contact with GP and the outpatient respiratory department. Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered. If a patient changes his/her mind and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation).
Sponsors
Copenhagen University Hospital, Hvidovre
University Hospital Bispebjerg and Frederiksberg
Hillerod Hospital, Denmark
Herlev and Gentofte Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Masking description
Participants will be informed that the trial is assessing the impact of pulmonary rehabilitation models on predetermined outcomes, but not the specific nature of the models of interest, and the predetermined hypothesis of the intervention group allocated to. All assessors are blinded to group allocation and previous test results. In case of failure keeping the outcome assessor blinded (that is, if a participant reveals his/her allocation) a second assessor will be available to step in and conduct the assessment on another day. To avoid investigators (subconscious) bias the biostatistician who perform the data analyses and validate the results is blinded to group allocation. The research group will interpret the results, before the allocation code is broken.
Intervention model description
A randomized clinical, assessor- and statistician blinded multicentre trial with three parallel-groups
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Indication for pulmonary rehabilitation according to Danish national guidelines * Unable to access and participate in the conventional out-patient hospital- or community-based PR when offered during routine consultation * A post-bronchodilator ratio FEV1/FVC \<70% (confirmed physician diagnosis of COPD) * A post-bronchodilator FEV1 \<80% (degree of airway obstruction) corresponding to GOLD grade 2-4 (moderate to very severe) * GOLD group B, C, D corresponding to severe respiratory symptoms and/or frequent acute exacerbations * Able to stand up from a chair (height 44-46cm) and walk 10 meters independently (with or without a walking aid) * Able to lift both arms to a horizontal level with a minimum of 1 kilogram's dumbbells in each hand
Exclusion criteria
* Participation in conventional PR in the past 24 months * Cognitive impairment - unable to follow instructions * Impaired hearing or vision - unable to see or hear instruction from a tablet * Unable to understand and speak Danish * Comorbidities where the exercise content is contraindicated (e.g. treatment for diabetic foot ulcer, active cancer treatment, life expectancy \<12-months)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in COPD Assessment Test (CAT) | Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint) | Patient completed questionnaires that assess respiratory symptoms. Eight item questionaire with total score from 0-40 points. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in 1-minute sit-to-stand test (1-min-STS) | Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint) | measures endurance |
| Change in 30seconds sit-to-stand test (30sec-STS) | Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint) | measures muscle strength |
| Change in Short Physcial Performance Battery (SPPB) | Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint) | Measures frailty/possible sarcopenia/ mobility disaabilities |
| Change in Handgrip strength (JAMAR) | Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint) | measures handgrip muscle strength in kilo. High is better |
| Changes in objectively measured physical acitivity (50% of total sample) | Baseline; 10-weeks from baseline ( primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint) | Devise is ActivePAL triaxial accelerometer (PAL Technologies Ltd., Glascow, UK). Wearing time is 24 h per day for 5 days at each time point. Measures sedentary and active body movements, steps per day and METs. High number of activity is better |
| Change in Hospital Anxiety and Depression Scale (HADS) | Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint) | Patient completed questionnaires that assess anxiety and depression symptoms. Seven item domain questions for depression with total score form 0-21 point. Seven item domain questions for anxiety with total score fra 0-21 points. |
| Change in Euro Qol (EQ5D-3L) | Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint) | Patient completed questionnaires that assess quality of life. Total score fra 0-1 on EQ5D-health domain. Total score from 0-100mm on EQ5D-vas domain. No total domain score |
| Change Brief Pain Inventory (BPI) | Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint) | Patient completed questionnaires that assess pain. Low score is better |
| Change Multidimensional Fatigue Inventory (MFI-20) | Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint) | Patient completed questionnaires that assess pain. Low score is better |
| Change Pittsburg Sleep Quality Index (PSQI) | Baseline; 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint) | Interview completed questionnaire that assess sleep quality. Low score is better |
| Program completion | at 10-weeks from baseline (primary endpoint); 75-weeks from baseline (secondary endpoint) | The number of participants who complete their allocated rehabilitation program (attend at least 70% of planned sessions). |
| Number of hospital admissions (respiratory related and all-cause) | at 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint) | Total number |
| Mortality (respiratory related and all-cause) | at 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint) | Total number |
| Adverse events | at 10-weeks from baseline (primary endpoint); 35-weeks from baseline; 75-weeks from baseline (secondary endpoint) | numbers of SAE and AE |
Countries
Denmark
Contacts
PRINCIPAL_INVESTIGATORHenrik Hansen, PhD
Dept. of Respiratory Medicine, University Hospital Hvidovre
STUDY_CHAIRNina Godtfredsen, MD, PhD
Dept. of Respiratory Medicine, University Hospital Hvidovre
Outcome results
None listed